Graft Versus Host Disease (GvHD) Treatment Market Report and Forecast 2024-2032

Graft Versus Host Disease (GvHD) Treatment Market Size

The graft versus host disease (GvHD) treatment market is expected to grow at a CAGR of 8.50% during the forecast period of 2024-2032, driven by rising development of new therapeutic options, surge in clinical research, and growing awareness and diagnosis of GvHD across the 8 major markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Graft Versus Host Disease (GvHD) Treatment Market Outlook

• Increased investment in R&D is leading to the development of new treatments including monoclonal antibodies, kinase inhibitors, and cell-based therapies, which is poised to elevate the market value.

• The rising number of allogeneic stem cell transplants and the increased healthcare expenditure are expected to drive the market demand.

• The rise in strategic partnerships among the key market players is a major market trend.

Graft Versus Host Disease (GvHD) Treatment Market Overview

Graft versus host disease refers to a complication pertaining to allogeneic stem cell transplantation in which the body treats the donated stem cells as foreign objects leading to an attack against them. It is a potentially serious disease that is usually caused due to significant differences in the body of the host and the donor. Chronic graft versus host disease (cGvHD) is a common type of the condition can be lethal, necessitating patients to get great care in order to survive.

 
A significant portion of adults and children surviving for more than 100 days after transplants are affected by chronic graft versus host disease (cGvHD). This propels the demand for immunosuppressive medications, which impacts the graft versus host disease (GvHD) treatment market dynamics. Moreover, cGvHD can appear after a few days, or after several years post-transplant. It might occur in the skin, liver, mouth, or lungs, and the symptoms are usually vague. Hence, over the forecast period, the anticipated increase in the introduction of new and effective therapeutic options, including biologics and targeted therapies, is likely to aid the market growth. Significant investments in research and development by pharmaceutical companies, improved diagnostic techniques, and favourable regulatory environments are some of the factors influencing the market landscape.

Graft Versus Host Disease (GvHD) Treatment Market Growth Drivers

Development of New Therapies to Meet Rising Graft Versus Host Disease (GvHD) Treatment Demand

The surge in clinical research activities, supported by substantial fundings, is resulting in the introduction of new treatment options. For instance, in June 2023, a phase III study published in the New England Journal of Medicine revealed a new standard of care for graft-versus-host disease prevention following stem cell transplant. More effective and having a better safety profile than the current standard of treatment (calcineurin inhibitor and methotrexate), this alternative therapy included the regimen of three drugs i.e., cyclophosphamide, tacrolimus, and mycophenolate mofetil. The findings reported that more than half of the patients who took the experimental therapy were alive, free of grade III-IV acute GVHD and chronic GVHD requiring immunosuppression and without disease relapse or progression. Thus, the rising development of effective drug therapies to prevent severe cases of the disorder is a significant driver of the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Graft Versus Host Disease (GvHD) Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Graft Versus Host Disease (GvHD) Treatment Segmentation

Market Breakup by Disease Type
 

• Acute Graft Versus Host Disease (aGvHD)

• Chronic Graft Versus Host Disease (cGvHD)

Market Breakup by Treatment Type

• Drugs
  • Corticosteroids
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
  • Immunosuppressants
  • Others

• Therapies

Market Breakup by Route of Administration

• Oral

• Injectable

• Others

Market Breakup by Gender

• Male

• Female

Market Breakup by Patient Type

• Adult

• Pediatric

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Transplant Centers

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Graft Versus Host Disease (GvHD) Treatment Market Share

Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

The market segmentation by treatment type includes drugs and therapies. Drugs are further divided into corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors, and immunosuppressants, among others, and therapies. Corticosteroids experience a high market demand owing to their anti-inflammatory and immunosuppressive properties and are often the first line of treatment. Monoclonal antibodies, such as rituximab and infliximab, help in managing the symptoms of this systemic disorder by targeting specific immune components. Immunosuppressants are also widely used in the treatment regimen to suppress the immune response, thereby preventing donor cells from attacking host tissues.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Graft Versus Host Disease (GvHD) Treatment Market Analysis by Region

The segmentation based on the region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds majority of the market share owing to increasing healthcare awareness and stringent government regulations aimed towards advancing medical services. In addition to this, the growing geriatric population and increasing prevalence of lifestyle-related issues such as obesity, are anticipated to accelerate the market growth in the region.

EU-4 and the United Kingdom are also projected to hold a significant market share, attributed to the presence of affluent academic institutions and healthcare companies in the region. The robust medical research infrastructure also boosts the market value.

Leading Players in the Graft Versus Host Disease (GvHD) Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Incyte Corporation

This American multinational pharmaceutical company is a leading player in the market, known for developing innovative therapies. Its key product is Jakafi® (ruxolitinib ) is used for treating acute graft-versus-host disease (aGVHD) for patients who don't show desired response to corticosteroid treatment.

Sanofi

This innovative global healthcare company invests heavily in the development of effective medications and significantly contributes to the graft versus host disease (GvHD) treatment market growth. Sanofi is a developer of Rezurock® (belumosudil), which is approved in the United States for the treatment of chronic graft-versus-host disease.

Mesoblast Ltd

Mesoblast Limited, an Australian regenerative medicine company, is engaged in the clinical development of cellular medicines for diseases with unmet medical needs. Its drug candidate Remestemcel-L is being developed for the treatment of acute graft versus host disease.

AbbVie Inc.

United States-based biomedical company AbbVie Inc. is one of the leading players in the market. In August 2022, AbbVie’s Bruton's tyrosine kinase inhibitor (BTKi) treatment IMBRUVICA® (ibrutinib) received FDA approval for the treatment of chronic graft versus host disease in the pediatric patient population.

Other key players in the market include Bristol Myers Squibb, Sun Pharmaceutical Industries Ltd., Novartis AG, Janssen Global Services, LLC, and Astellas Pharma, Inc.

Key Highlights of the Report

Graft Versus Host Disease (GvHD) Treatment Market Report Snapshots

Graft Versus Host Disease (GvHD) Treatment Market Size

Graft Versus Host Disease (GvHD) Treatment Market Growth

Graft Versus Host Disease (GvHD) Treatment Market Trends

Graft Versus Host Disease (GvHD) Treatment Market Share

Graft Versus Host Disease (GvHD) Treatment Market Regional Analysis

Graft Versus Host Disease (GvHD) Treatment Companies

Key Questions Answered in the Graft Versus Host Disease (GvHD) Treatment Market Report

• What was the graft versus host disease (GvHD) treatment market value in 2023?
• What is the graft versus host disease (GvHD) treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on disease type?
• What is the market breakup based on treatment type?
• What is market segmentation based on the route of administration?
• What is the market breakup by gender?
• What is the market breakup based on patient type?
• Who are the major end users in the market?
• What are the major distribution channels in the market?
• What are the major factors aiding the graft versus host disease (GvHD) treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to witness expedited growth during the forecast period? 
• What are the major graft versus host disease (GvHD) treatment market trends?
• How does the rise in the geriatric population impact the market size?
• What disease type will dominate the market share? 
• Which treatment type is expected to have a high market value in the coming years?
• Which route of administration will experience the elevated demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Which gender is poised to considerably impact the market demand? 
• Which patient type is likely to elevate the market value?
• Which distribution channel is anticipated to boost the market share?
• Who are the key players involved in the graft versus host disease (GvHD) treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?